Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenues:
Total revenue	$ 1,291	$ 6,920	$ 2,567	$ 9,148
Operating expenses:
Cost of product sales	(25)	(15)	(401)	(15)
Research and development expenses	(3,486)	(5,601)	(14,930)	(21,213)
Selling, general and administrative expenses	(10,997)	(18,503)	(35,094)	(45,339)
Total operating expenses	(14,508)	(24,119)	(50,425)	(66,567)
Loss from operations	(13,217)	(17,199)	(47,858)	(57,419)
Other income (expense):
Other income (expense), net	450	(10)	614	116
Interest income	5	94	85	176
Interest expense	(261)	(709)	(1,536)	(2,512)
Loss on extinguishment of debt			(2,757)
Loss before income taxes	(13,023)	(17,824)	(51,452)	(59,639)
Income tax benefit (expense)	72	29	(199)	(80)
Net loss	$ (12,951)	$ (17,795)	$ (51,651)	$ (59,719)
Loss per share
Basic and Diluted ($ per share)	$ (0.09)	$ (0.24)	$ (0.44)	$ (0.83)
Weighted average number of shares:
Basic and Diluted	144,690,904	75,161,192	117,454,536	72,153,405
Product revenue, net
Revenues:
Total revenue	$ (47)	$ 1,445	$ 61	$ 1,445
Collaboration revenue
Revenues:
Total revenue	616	5,051	768	6,051
Research premium and grant revenue
Revenues:
Total revenue	$ 722	$ 424	$ 1,738	$ 1,652